Gregorio Marañón Hospital in Madrid, Spain

Two 2018 studies from Gregorio Marañón Hospital in Madrid, Spain reported findings about the ability of the T2Candida® Panel to predict patient outcomes:

 

  • Strong indicator of complications: Positive T2Candida Panel results identified patients who had an over 30x increased likelihood of developing health complications, including mortality.
  • Strong indicator of poor outcomes: The T2Candida Panel is a better predictor of patients at risk of having poor outcomes than existing diagnostic tests. A negative T2Candida Panel result may significantly shorten the duration of antifungal therapy for 67% of patients.
  • Improved distinction between complicated and uncomplicated infection: The T2Candida Panel distinguishes between complicated and uncomplicated infection better than available diagnostic tests.

 

“The predictive value of the T2Candida Panel represents an important advance in our understanding of the clinical uses of T2Dx diagnostics. A T2Candida Panel positive demonstrated a 30x increase in the likelihood of a complicated infection and showed significant advantages over beta-D-glucan, blood culture and CAGTA,” said Patricia Muñoz, M.D., Ph.D., Division of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain. “Together, these studies demonstrate that the T2Dx Instrument is a powerful stewardship tool that can help inform clinicians when they can safely reduce the use of antimicrobial drugs – or when a patient needs more aggressive treatment.”

Rigshospitalet, Denmark

T2Candida data published in 2019 from a high risk ICU population at Righospitalet in Denmark found “T2Candida was superior to blood culture and mannan antigen and may improve diagnosis.”

The study found 10/11 T2Candida positives were supported by culture isolates. The authors point out that T2Candida performance may be even better but bias is introduced by the imperfect gold standard.

The paper shows T2Candida positivity for an average of 3 days longer than blood culture. The authors discuss how T2Candida may be able to support stewardship efforts because resolution of symptoms and T2Candida negativity may be able to reduce the appropriate duration of therapy to shorter than standard 14 days.

Read the poster presented at ASM Microbe (2016) in Boston, MA, by investigators from Statens Serum Institut.

Gemelli Hospital, Italy

Prof. Maurizio Sanguinetti, MD of Gemelli Hospital, Italy presented at the GREAT conference how T2Bacteria can help critical care and emergency medicine clinicians to:

  • Rapidly diagnose and treat some of the most common and deadly pathogenic organisms.
  • Demonstrate how rapid diagnostics can be a “game changer” in the microbiology lab.

The delay of microbial culture results often make them unhelpful for the clinician, but T2Bacteria achieves the “need for speed” in the clinical setting. Prof. Sanguinetti presented Gemelli Hospital’s T2Bacteria data published in the Journal of Antimicrobial Chemotherapy demonstrating:

  • Positive results more than 4.5 times faster than blood culture
  • Negative results more than 20 times faster than blood culture
  • 66.7% of the clinically infected patients missed by blood culture were correctly identified by T2Bacteria and these patients were being inappropriately treated at the time of the T2Bacteria result.

La Paz Hospital University, Spain

A powerful case study from Spain was published in the peer-reviewed Medical Mycology Case Reports. The study details how the T2Candia Panel contributed to the healthy discharge of a 1-year-old transplant patient suspected of sepsis by providing infection results far earlier than blood culture and leading to more targeted antifungal therapy. The T2Candida Panel provided “optimal management of candidemia in this patient” and led to targeted therapy in hours of the first blood draw (while blood culture was sterile).

 

Fig. 1. Timeline of candidemia diagnosis and candidemia clearance through simultaneous blood cultures and T2Candida® tests.

Falces-Romero I., et al. Medical Mycology Case Reports, 2018.